Funding awarded
- Fast Track Phase II - Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H awarded by National Heart, Lung, & Blood Institute Principal Investigator Subaward 2025 - 2027
- missing activity Principal Investigator Subaward 2024 - 2025
- missing activity Principal Investigator Subaward 2024 - 2025